Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
S. Leijen
No relevant relationships to disclose
M. R. Middleton
No relevant relationships to disclose
P. Tresca
No relevant relationships to disclose
F. Kraeber-Bodere
Consultant or Advisory Role - Roche
Honoraria - PET reader
V. Dieras
Consultant or Advisory Role - Roche
Other Remuneration - Amgen; Pfizer; Roche
M. E. Scheulen
No relevant relationships to disclose
J. Tessier
Employment or Leadership Position - Roche
Z. X. Xu
Employment or Leadership Position - Roche
Stock Ownership - Roche
E. Shochat
Employment or Leadership Position - Roche
A. Walz
Employment or Leadership Position - Roche
J. Deutsch
Employment or Leadership Position - Roche
Stock Ownership - Roche
S. Blotner
Employment or Leadership Position - Roche
V. Lopez Valverde
Employment or Leadership Position - Roche
V. M. Naegelen
Employment or Leadership Position - Roche
J. H. M. Schellens
Consultant or Advisory Role - Roche
Research Funding - Roche
W. E. Eberhardt
Consultant or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Merck Sharp & Dohme; Novartis; OSI Pharmaceuticals; Pfizer; Roche; Sanofi ; Schering-Plough
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; OSI Pharmaceuticals; Pfizer; Roche; Sanofi ; Schering-Plough